Search

The real-time measurement and control of clean-energy power parameters provides a reliable platform for the performance test, a working state simulation of clean-energy power system and effective supports for the reasonable design of clean-energy power system. The whole measurement and control system is controlled by PLC and monitored by Kingview software. While mainly controlling the voltage and electric quantity of storage battery and motor speed, PLC is responsible for Modbus communication between the storage battery management system, the motor controller, the dynamometer controller and the industrial personal computer, Kingview is used for the real-time measurement and the controlling of system power parameters. The test shows that the measurement and control system is stable and reliable.

This paper introduces the rapid prototyping technology of electronic throttle system based on MotoHawk platform. It builds the mathematical model of the electronic throttle, then designs and verifies incremental PID controller algorithm in Matlab/Simulink. Using MotoTron company's advanced technology to set up electronic throttle development platform. Through transplanting strategy and the calibration test after downloading finally realizes the optimization of control performance.

Background Diabetic nephropathy (DN) is the major complication of diabetes; proteinuria is the hall mark of DN. Currently, the treatment for proteinuria is mainly limited to angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). According to Traditional Chinese Medicine (TCM) theory, Chinese medicinals ‘securing essence and tonifying the kidney’ may be appropriate for proteinuria. The most promising Chinese medicinals and formulae are introduced in the present study to form a potent formula for DN proteinuria. To make oral administration convenient, the formula will be processed in the form of granules. Methods/design A randomized, multi-center pilot trial will be conducted. Forty eight participants with DN will be randomly assigned to one of four treatment groups: 1. A granule group, at 10 grams, three times daily (G10 group, n = 12); 2. A granule group, at 20 grams, three times daily (G20 group, n = 12); 3. A decoction group (D group, n = 12); and 4. An irbesartan group (Aprovel group, n = 12). The following outcome measures will be used: the percentage change of the albumin-to-creatinine ratio; and the changes in serum creatinine, glomerular filtration rate, fasting plasma glucose and hemoglobulin from baseline to the end of the trial. Discussion It is notable that most published clinical trials which assessed the efficacy of TCM on DN were of poor methodology and, therefore, their results have been invalidated. It is necessary to carry out well-designed clinical trials to provide sound evidence. The present trial is a study with potentially great value, for it will provide the parameters for future randomized, placebo-controlled, clinical trials with large sample sizes. Trial registration The trial is registered on the Chinese Clinical Trial Registry: ChiCTR-TRC-12002718 (http://www.chictr.org/cn/proj/show.aspx?proj=3820).